Azithromycin in children: A critical review of the evidence

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 1, 2002, Pages 54-76

  Pacifico, Lucia ^a,b   Chiesa, Claudio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

Author keywords

Azithromycin; Compromised host; Pediatric infections; Respiratory tract infections

Indexed keywords

AZITHROMYCIN; MACROLIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CAT SCRATCH DISEASE; CHLAMYDOPHILA PNEUMONIAE; CRYPTOSPORIDIOSIS; EVIDENCE BASED MEDICINE; HUMAN; INFECTION; LEGIONELLA; LEGIONNAIRE DISEASE; MEDLINE; MYCOBACTERIUM AVIUM; MYCOPLASMA PNEUMONIA; OTITIS MEDIA; PERTUSSIS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PYOGENES; TONSILLITIS; TRACHOMA; TYPHOID FEVER; URETHRITIS; UTERINE CERVICITIS;

EID: 0036157462     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80007-8     Document Type: Article

References (99)

1. Tissue-directed pharmacokinetics
2. The pharmacokinetics of azithromycin in human serum and tissues
3. Pharmacokinetics and pharmacodynamics of newer macrolides
4. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children
5. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides
6. Clinical tolerability and safety of azithromycin in children
7. Clarithromycin and azithromycin: New macrolide antibiotics
8. The new macrolide antibiotics: Azithromycin, clarithromycin, dirithromycin, and roxithromycin
9. Clinical microbiology of azithromycin
10. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta
11. Infections caused by erythromycin-resistant Streptococcus pneumoniae: Incidence, risk factors, and response to therapy in a prospective study
12. Antibiotic-resistant pneumococcal disease in South African children
13. Resistance to erythromycin in group A streptococci
14. Sensitivity of group A streptococci to antibiotics. Prevalence of resistance to erythromycin in Japan
15. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children
16. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum
17. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae
18. Macrolide antibiotics in pediatric infectious diseases
19. New approaches to the treatment of group A streptococcal pharyngitis
20. Management of pediatric patients with group A beta-hemolytic Streptococcus pharyngitis: Treatment options
21. Multicentre evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children
22. Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis
23. Evaluation of the efficacy, safety and toleration of azithromycin vs penicillin V in the treatment of acute streptococcal pharyngitis in children: Results of a multicenter, open comparative study
24. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children
25. Multicentre comparison of azithromycin versus erythromycin in the treatment of paediatric pharyngitis or tonsillitis caused by group A streptococci
26. Azithromycin versus cefaclor in the treatment of pediatric patients with acute group A beta-hemolytic streptococcal tonsillopharyngitis
27. Short course therapy with ceftibuten versus azithromycin in pediatric streptococcal pharyngitis
28. The group A streptococcal upper respiratory tract carrier state: An enigma
29. Middle ear disease and the practice of pediatrics. Burden during the first five years of life
30. Epidemiology of otitis media during the first seven years of life in children in greater Boston: A prospective, cohort study
31. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children
32. Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children
33. A comparative study of azithromycin and amoxycillin in paediatric patients with acute otitis media
34. A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school
35. A multicenter, double blind comparison of azithromycin and amoxicillin/ clavulanate for the treatment of acute otitis media in children
36. An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media
37. Comparative trial of 3-day azithromycin versus 10-day amoxycillin/clavulanate potassium in the treatment of children with acute otitis media with effusion
38. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion
39. A multicenter, open label trial of azithromycin vs amoxicillin/ clavulanate for the management of acute otitis media in children
40. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media
41. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media
42. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children
43. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The "Pollyanna phenomenon"
44. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States
45. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
46. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: Comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate
47. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections
48. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children
49. Etiology and treatment of community-acquired pneumonia in ambulatory children
50. Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections
51. Oral antibiotic therapy for uncomplicated bacterial skin infections in children
52. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy
53. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections
54. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections
55. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin
56. Short-term treatment of pertussis with azithromycin in infants and young children
57. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus
58. In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex
59. In vitro and in vivo activities of clarithromycin against Mycobacterium avium
60. Mycobacterium avium complex
61. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS
62. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
63. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy
64. Future indications for macrolides
65. Global data on blindness
66. Nonocular Chlamydia infection and the risk of ocular reinfection after mass treatment in a trachoma hyperendemic area
67. Extraocular infections in children in areas with endemic trachoma
68. Randomised controlled trial of single-dose azithromycin in treatment of trachoma
69. 1998 Guidelines for treatment of sexually transmitted diseases
70. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study
71. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children
72. Macrolides and Clindamycin
73. Multidrug-resistant Salmonella typhi: A worldwide epidemic
74. Quinolone-resistant Salmonella typhi in Viet Nam: Molecular basis of resistance and clinical response to treatment
75. Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children
76. In vitro activity of azithromycin against bacterial enteric pathogens
77. Comparative efficacies of azithromycin and ciprofloxacin against experimental Salmonella typhimurium infection in mice
78. Distribution of orally administered azithromycin in various blood compartments
79. Efficacy of azithromycin for typhoid fever
80. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance
81. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India
82. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever
83. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children
84. MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolates
85. Antibiotic therapy for cat-scratch disease: Clinical study of therapeutic outcome in 268 patients and a review of the literature
86. Azithromycin for the treatment of cat-scratch disease
87. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease
88. Bartonella species, including cat-scratch disease
89. Treatment of cat-scratch disease
90. The infectivity of Cryptosporidium parvum in healthy volunteers
91. Chronic cryptosporidiosis in patients with AIDS: Stable remission and possible eradication after long-term, low dose azithromycin
92. Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis
93. Azithromycin for treatment of severe Cryptosporidium diarrhea in two children with cancer
94. Azithromycin therapy for Cryptosporidium parvum infection in four children with human immunodeficiency virus
95. Legionellosis
96. Antimicrobial chemotherapy for Legionnaires' disease: A review
97. In vitro activity of macrolides against intracellular Legionella pneumophila
98. Legionnaires' disease and pneumonia. Beware the temptation to underestimate this "exotic" cause of infection